selected scholarly activity
-
academic article
- Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry. Journal of Global Antimicrobial Resistance. 24:335-339. 2021
- Standard versus combined chemical, mechanical, and heat decontamination of hospital drains harboring carbapenemase-producing organisms (CPOs): A randomized controlled trial. Infection Control and Hospital Epidemiology. 1-4. 2021
- Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older. JGH Open. 5:253-257. 2021
- Carbapenemase-producing Enterobacterales in hospital drains in Southern Ontario, Canada. Journal of Hospital Infection. 106:820-827. 2020
- Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health. 20:1345. 2020
- Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver International. 40:1841-1852. 2020
- Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Journal of Hepatology. 71:660-665. 2019
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis. 26:1127-1138. 2019
- Infection prevention and control practices related to carbapenemase-producing Enterobacteriaceae (CPE) in acute-care hospitals in Ontario, Canada. Infection Control and Hospital Epidemiology. 40:1006-1012. 2019
- Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. Open Forum Infectious Diseases. 6:ofz076. 2019
- Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. Journal of Infectious Diseases. 218:1722-1729. 2018
- Emergence of Carbapenemase-Producing Enterobacteriaceae, South-Central Ontario, Canada1. Emerging Infectious Diseases. 24:1674-1682. 2018
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 153:113-122. 2017
- Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clinical Infectious Diseases. 65:13-19. 2017
- FibroScan® access in Canada: Time for reform, a call for universal access.. Canadian Journal of Gastroenterology and Hepatology. 29:221-222. 2015
- Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Canadian Journal of Gastroenterology. 29:220-221. 2015
- Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. Canadian Journal of Gastroenterology and Hepatology. 29:125-129. 2015
- Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada. Clinical Infectious Diseases. 55:e109-e117. 2012
- Brucellosis in a returned traveller. CMAJ. 183:E690-E692. 2011
- Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Medical Mycology. 44:659-664. 2006
- Group A Streptococcal Sepsis Secondary to Peritonitis and Acute Pelvic Inflammatory Disease. European Journal of Clinical Microbiology and Infectious Diseases. 20:0437-0439. 2001
- Reduced Virulence of Group A Streptococcal Tn916 Mutants That Do Not Produce Streptolysin S. Infection and Immunity. 66:1671-1679. 1998
- Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization.. Infection and Immunity. 64:2643-2648. 1996
-
conference paper
- PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR: RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY. Hepatology. 981A-981A. 2019
- Sofosbuvir-velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. Journal of Gastroenterology and Hepatology (Australia). 102-102. 2019
- IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. Gut. A138-A138. 2019
- Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry. Journal of Hepatology. E508-E508. 2019
- GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. Journal of Hepatology. e2-e3. 2019
- THU-179-Never too old to be direct acting antiviral treated for hepatitis C virus. Journal of Hepatology. e240-e241. 2019
- THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort. Journal of Hepatology. e328-e328. 2019
- Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis. Hepatology. 1456A-1456A. 2018
- Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World. Hepatology. 360A-361A. 2018
- Efficacy and safety of Sofosbuvir/Velpatasvir for the treatment of treatment-naive, non-cirrhotic patients with chronic hepatitis C genotype 3 infection: integrated analysis of three phase 3 clinical trials. Journal of Viral Hepatitis. 196-197. 2018
- Z-PROFILE: real-world utilization and effectiveness of Elbasvir/Grazoprevir in adult patients with chronic hepatitis C in Canada - final study results. Journal of Viral Hepatitis. 68-68. 2018
- Z-PROFILE: Real-world utilization and effectiveness of elbasvir/ grazoprevir in adult patients with chronic hepatitis C in Canada. Journal of Hepatology. S295-S296. 2018
- Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens. Hepatology. 121A-121A. 2017
- Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study. Journal of Hepatology. S307-S308. 2017
- A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study. Hepatology. 135A-136A. 2016
- Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks is Effective and Safe in Treatment-Naïve Genotype-3 Hepatitis C-Infected Patients in Canada. Journal of Hepatology. S781-S781. 2016
- Cloning of a Chromosomal Region Responsible for Streptolysin S Production in Streptococcus pyogenes. Advances in Experimental Medicine and Biology. 733-736. 1997